The growth hormone insensitivity (GHI) syndrome was first described by Laron et al. (1) in three siblings of Israeli origin in 1966. Characteristically, these patients share the same clinical and biochemical features of the patients with GH deficiency, although the basal circulating levels of GH are high (1, 2) . In this rare autosomal recessive disorder the inability to generate normal quantities of insulin-like growth factor I (IGF-I) results in severe postnatal growth failure and markedly reduced adult height (3) . The primary defect is located in the growth hormone receptor level (4) . The (9) (10) (11) . This finding is no longer a prerequisite for the diagnosis of GHI (12) (13) (14) .
In 
